Key result
Chronic L-NAME administration lowered aortic cGMP (530 vs 1798 fmol/mg protein in controls, P<.05) and decreased contractile responses, which were restored by quinapril.
Why the study?
Does quinapril alter vascular reactivity and cGMP content in L-NAME-induced hypertensive Wistar rats?
Does quinapril alter vascular reactivity and cGMP content in L-NAME-induced hypertensive Wistar rats?
Absolute Event Rate: 530% vs 1798%
p-value: p=< .05
In a rat model of L-NAME-induced hypertension, ACE inhibition with quinapril prevents blood pressure rise and restores contractile capacity without normalizing aortic cGMP levels or acetylcholine-induced dilation.
No takes yet. Share an insight, caveat, or question.
Does not inform clinical hypertension management; leaves open quinapril's role in restoring vascular reactivity in nitric oxide-deficient models.
Henrion et al. (1996) studied L-NAME-induced hypertension (n=36). L-NAME or L-NAME plus quinapril vs. Controls was evaluated on Aortic cGMP content (p=< .05). Chronic L-NAME administration lowered aortic cGMP (530 vs 1798 fmol/mg protein in controls, P<.05) and decreased contractile responses, which were restored by quinapril.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: